# Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

> **NCT03372200** · PHASE3 · COMPLETED · sponsor: **Mochida Pharmaceutical Company, Ltd.** · enrollment: 203 (actual)

## Conditions studied

- Hyperuricemia With or Without Gout

## Interventions

- **DRUG:** FYU-981
- **DRUG:** Febuxostat

## Key facts

- **NCT ID:** NCT03372200
- **Lead sponsor:** Mochida Pharmaceutical Company, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-09
- **Primary completion:** 2018-06-04
- **Final completion:** 2018-07-05
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2018-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03372200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03372200, "Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03372200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*